Europe Synthetic Peptide Vaccine Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Synthetic Peptide Vaccine Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 1 ml Market Performance (Volume)
  • 2.1.2 2.5 ml Market Performance (Volume)
  • 2.1.3 Other Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 1 ml Market Performance (Value)
  • 2.1.2 2.5 ml Market Performance (Value)
  • 2.1.3 Other Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Prostate Cancer Market Performance (Volume)
  • 3.1.2 Breast Cancer Market Performance (Volume)
  • 3.1.3 Gastric Cancer Market Performance (Volume)
  • 3.1.4 Lung Cancer Market Performance (Volume)
  • 3.1.5 Other Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Artificial Cell Technologies
  • 4.1.1 Artificial Cell Technologies Profiles
  • 4.1.2 Artificial Cell Technologies Product Information
  • 4.1.3 Artificial Cell Technologies Synthetic Peptide Vaccine Business Performance
  • 4.1.4 Artificial Cell Technologies Synthetic Peptide Vaccine Business Development and Market Status
• 4.2 Benovus Bio
  • 4.2.1 Benovus Bio Profiles
  • 4.2.2 Benovus Bio Product Information
  • 4.2.3 Benovus Bio Synthetic Peptide Vaccine Business Performance
  • 4.2.4 Benovus Bio Synthetic Peptide Vaccine Business Development and Market Status
• 4.3 Bionor Pharma
  • 4.3.1 Bionor Pharma Profiles
  • 4.3.2 Bionor Pharma Product Information
  • 4.3.3 Bionor Pharma Synthetic Peptide Vaccine Business Performance
  • 4.3.4 Bionor Pharma Synthetic Peptide Vaccine Business Development and Market Status
• 4.4 Circassia
  • 4.4.1 Circassia Profiles
  • 4.4.2 Circassia Product Information
  • 4.4.3 Circassia Synthetic Peptide Vaccine Business Performance
  • 4.4.4 Circassia Synthetic Peptide Vaccine Business Development and Market Status
• 4.5 Celgene Corporation
  • 4.5.1 Celgene Corporation Profiles
  • 4.5.2 Celgene Corporation Product Information
  • 4.5.3 Celgene Corporation Synthetic Peptide Vaccine Business Performance
  • 4.5.4 Celgene Corporation Synthetic Peptide Vaccine Business Development and Market Status
• 4.6 Galena Biopharma
  • 4.6.1 Galena Biopharma Profiles
  • 4.6.2 Galena Biopharma Product Information
  • 4.6.3 Galena Biopharma Synthetic Peptide Vaccine Business Performance
  • 4.6.4 Galena Biopharma Synthetic Peptide Vaccine Business Development and Market Status
• 4.7 Immatics biotechnologies
  • 4.7.1 Immatics biotechnologies Profiles
  • 4.7.2 Immatics biotechnologies Product Information
  • 4.7.3 Immatics biotechnologies Synthetic Peptide Vaccine Business Performance
  • 4.7.4 Immatics biotechnologies Synthetic Peptide Vaccine Business Development and Market Status
• 4.8 Immune Design
  • 4.8.1 Immune Design Profiles
  • 4.8.2 Immune Design Product Information
  • 4.8.3 Immune Design Synthetic Peptide Vaccine Business Performance
  • 4.8.4 Immune Design Synthetic Peptide Vaccine Business Development and Market Status
• 4.9 ImmunoCellular Therapeutics
  • 4.9.1 ImmunoCellular Therapeutics Profiles
  • 4.9.2 ImmunoCellular Therapeutics Product Information
  • 4.9.3 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Business Performance
  • 4.9.4 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Business Development and Market Status
• 4.10 Invectys
  • 4.10.1 Invectys Profiles
  • 4.10.2 Invectys Product Information
  • 4.10.3 Invectys Synthetic Peptide Vaccine Business Performance
  • 4.10.4 Invectys Synthetic Peptide Vaccine Business Development and Market Status
• 4.11 ISA Pharmaceuticals
• 4.12 Lytix Biopharma
• 4.13 Bionor Pharma
• 4.14 Circassia
• 4.15 Celgene Corporation

5 Market Performance for Manufacturers

• 5.1 Europe Synthetic Peptide Vaccine Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Synthetic Peptide Vaccine Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Synthetic Peptide Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Synthetic Peptide Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Synthetic Peptide Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Synthetic Peptide Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Synthetic Peptide Vaccine Market Performance (Sales Point)

• 7.1 Europe Synthetic Peptide Vaccine Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Synthetic Peptide Vaccine Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Synthetic Peptide Vaccine Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Synthetic Peptide Vaccine Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Synthetic Peptide Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Prostate Cancer Industry
• 11.2 Breast Cancer Industry
• 11.3 Gastric Cancer Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Synthetic Peptide Vaccine Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Synthetic Peptide Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 1 ml Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 2.5 ml Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Other Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Prostate Cancer Sales and and Growth Rate 2019-2024
  • 12.4.3 Breast Cancer Sales and and Growth Rate 2019-2024
  • 12.4.4 Gastric Cancer Sales and and Growth Rate 2019-2024
  • 12.4.5 Lung Cancer Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Synthetic Peptide Vaccine Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Synthetic Peptide Vaccine Gross Profit Trend 2019-2024

13 Conclusion